Novavax statement on prototype vaccine’s broad immune responses and accelerated focus on Omicron BA.4/5 as recommended by the FDA.
Novavax is awaiting US emergency use authorization for its prototype COVID-19 vaccine and is committed to bringing it to market. Clinical data generated to-date demonstrate that this prototype vaccine offers broad immune responses including against circulating variants, such as the Omicron BA.4/5.
Novavax is already well underway in its variant program and will accelerate its focus on Omicron BA.4/5, as recommended by FDA in their guidance on June 30th. The company expects to have additional preclinical data on Omicron BA.4/5 in the late summer or fall, and expect to be in a position to provide an Omicron-containing vaccine in Q4 of this year.
Novavax continues to believe in the importance of vaccines that offer broad immune responses against a variety of variants, given the fact that COVID-19 will continue to evolve.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins